3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Small Cell Lung Carcinoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Acute
1
Infections
1
Hematologic Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
COVID-19
1
Breast Neoplasms
1
Anemia, Refractory, with Excess of Blasts
1
Adenocarcinoma Of Esophagus
1
Interventions
Surveys and Questionnaires
6
Standard of Care
6
Blood Specimen Collection
6
BNT162 Vaccine
5
Hydroxychloroquine
4
Surgical Procedures, Operative
3
Specimen Handling
3
Practice Guidelines as Topic
3
COVID-19 Vaccines
3
2019-nCoV Vaccine mRNA-1273
3
tocilizumab
2
sotrovimab
2
Pandemic Preparedness
2
CVnCoV COVID-19 vaccine
2
Azithromycin
2
sinovac COVID-19 vaccine
1
selinexor
1
remdesivir
1
ogalvibart
1
monalizumab
1
lenzilumab
1
heterologous prime boost COVID-19 vaccination
1
crexavibart
1
cilgavimab and tixagevimab drug combination
1
ciclesonide
1
avdoralimab
1
XAV-19
1
Therapeutics
1
Telemedicine
1
Sperm Count
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
COVID-19
×
monalizumab
×
Clear all
NCT04333914
2022-09-30
IMMUNONCOVID
Centre Leon Berard
Phase 2
Completed
19 enrolled